

**Table 1** Descriptive summary of the studies retained in the review

<b>Category</b>	<b>No.</b>	<b>Reference</b>
<i>Total no. of studies</i>	18	–
<i>Total no. of countries</i>	9	–
Bahrain	1	19
Egypt	1	20
Jordan	1	21
Lebanon	1	13
Morocco	4	14,22–24
Saudi Arabia	5	25–29
Syrian Arab Republic	1	30
Sudan	1	31
United Arab Emirates	3	12,15,16
<i>Demographics of studies</i>		
Women	7	13,16,19,20,25,26,31,
Parents	3	14,23,30
Men	1	15
<i>Healthcare clinicians &amp; students</i>	6	12,21,22,27–29
<i>Adolescents and young adults</i>	1	24
<i>Knowledge and awareness of HPV</i>	9	
<i>Reported prevalence &gt; 80%</i>	1	12
<i>Reported prevalence 30–80%</i>	5	15,16,19,20,26
<i>Reported prevalence &lt; 30%</i>	4	14,23,24,29
<i>Awareness of causal link HPV infection–cervical cancer</i>	10	
<i>Reported prevalence &gt; 80%</i>	3	12,13,22
<i>Reported prevalence 30–80%</i>	4	25,27,28,31
<i>Reported prevalence &lt; 30%</i>	3	
<i>Knowledge and awareness of anti-HPV vaccine</i>	9	
<i>Reported prevalence &gt; 80%</i>	1	12
<i>Reported prevalence 30–80%</i>	6	13,22,26,28–31
<i>Reported prevalence &lt; 30%</i>	2	14,21
<i>Acceptability of anti-HPV vaccine</i>	11	
<i>Reported prevalence &gt; 80%</i>	4	16,19,20,25
<i>Reported prevalence 30–80%</i>	6	12,14,15,23,26,29
<i>Reported prevalence &lt; 30%</i>	1	24

HPV = human papillomavirus.